| I-43 Emma Eckernäs Population pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine |
| I-44 Berfin Gülave Opioids distribution in human CNS might be altered due to pain-related increase of BBB permeability. |
| I-45 Heeyoon Jung Equivalent dose prediction of donepezil patch using population pharmacokinetic oral and patch combination model |
| I-46 Tatiana Karelina Quantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease |
| I-47 Orestis Papasouliotis Phase III dose selection for evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: exposure-response analyses from a phase II study in patients with multiple sclerosis |
| I-48 Satoshi Shoji Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies |
| I-49 Satoshi Shoji Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model |
| I-50 Hanna Silber Baumann Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers. |
